AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
ENP Newswire - 12 September 2013
Release date- 11092013 - AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD, today announced a worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775).
MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.
WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor MK-1775 is designed to cause certain tumour cells to divide without undergoing the normal DNA repair processes, ultimately leading to cell death. Preclinical evidence suggests that the combination of MK-1775 and DNA damage-inducing chemotherapy agents can enhance anti-tumor properties, in comparison to chemotherapy alone.
Under the terms of the agreement, AstraZeneca will pay Merck a $50 million upfront fee. In addition Merck will be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties. AstraZeneca will be responsible for all future clinical development, manufacturing and marketing.
'MK-1775 is a strong addition to AstraZeneca's growing oncology pipeline, which already includes a number of inhibitors of the DNA damage response,' said Susan Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit. 'The compound has demonstrated encouraging clinical efficacy data and we intend to study it in a range of cancer types where there is a high unmet medical need.'
'Merck is committed to advancing potentially meaningful therapeutic options promptly for patients with cancer,' said Iain D. Dukes, senior vice president and head of licensing and external scientific affairs at Merck. 'We are pleased to enter this agreement with AstraZeneca to realise the potential of MK-1775 while we focus on advancing our later stage oncology programs, MK-3475 and vintafolide.'
The agreement is contingent on expiration or termination of the waiting period under the Hart Scott-Rodino Antitrust Improvement Act
[Editorial queries for this story should be sent to firstname.lastname@example.org]
((Comments on this story may be sent to email@example.com))